NCT00664430 is a Phase 4 clinical trial of Calcitriol in Secondary Hyperparathyroidism, sponsored by Abbott.

Who is sponsoring NCT00664430?

NCT00664430 is sponsored by Abbott.

What drugs are being tested in NCT00664430?

Interventions in NCT00664430: Calcitriol, Paricalcitol.

What condition does NCT00664430 study?

NCT00664430 studies Secondary Hyperparathyroidism, Dialysis.

Is NCT00664430 still recruiting?

NCT00664430 is currently terminated. Last updated 18 January 2012.

Are results published for NCT00664430?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2012-01-18 · How we verify

NCT00664430

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects

Terminated Phase 4 Results posted Last updated 18 January 2012

What this trial tests

Phase 4 trial testing Calcitriol in Secondary Hyperparathyroidism in 13 participants. Terminated before completion.

Timeline

1 January 2009

Primary endpoint
1 June 2009

1 June 2009

Quick facts

Lead sponsor	Abbott
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	13
Start date	1 January 2009
Primary completion	1 June 2009
Estimated completion	1 June 2009
Sites	2 locations across Brazil

Drugs / interventions tested

Calcitriol (CALCITRIOL) — full drug profile →
Paricalcitol (PARICALCITOL) — full drug profile →

Conditions studied

Secondary Hyperparathyroidism — all drugs for Secondary Hyperparathyroidism →
Dialysis — all drugs for Dialysis →

Sponsor

Abbott — full company profile →

Who can join

18 and older, any sex, with Secondary Hyperparathyroidism or Dialysis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Proportion of Participants With a 50% Reduction in Parathyroid Hormone (PTH) Levels Relative to Visit 4 Values
Time frame: Up to Week 24
This outcome was measured at Visit 15, which could occur at different timepoints from study start, depending on the duration of each study period for each participant, relative to values on Visit 4. For participants who did not perform visit 4, the reduction of the PTH levels were to be assessed relative to visit 5 values.

Sponsor's own description

The primary objective of this study is to evaluate the efficacy and safety of paricalcitol in participants with moderate to severe secondary hyperparathyroidism (SHPT) undergoing hemodialysis who are resistant to treatment with calcitriol.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Calcitriol

Trials testing the same drug.

NCT06261905 — Vitamin D in OUD: Exploration of Alterations on the Dopamine D2/D3 Receptor System · Phase 1 · completed
NCT05415254 — Calcitriol Supplementation in COVID-19 Patients · NA · unknown
NCT04801303 — Evaluation of the Effects of Calcitriol's in the Neurological Symptoms of Friedreich's Ataxia Patients · Phase 4 · completed
NCT05765617 — Effect Of Calcitriol On Neutrophil To Lymphocytes Ratio And High Sensitivity C-Reactive Protein Covid-19 Patients · Phase 2 · completed
NCT04967469 — Comparison of Serum Calcium Level Between Preoperative Vitamin D and Non-vitamin D Regimen of Total Parathyroidectomy in · NA · completed

Other recruiting trials for Secondary Hyperparathyroidism

Currently open trials in the same condition.

NCT06130683 — Single-Cell Sequence Technology Used to Reveal Heterogeneity of Secondary Hyperparathyroidism · active not recruiting
NCT05880914 — Precision Medicine Approaches to Renal Osteodystrophy · recruiting
NCT03969329 — A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis · Phase 3 · recruiting
NCT03633708 — A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemo · Phase 3 · recruiting

Other Abbott trials

Trials by the same sponsor.

NCT06217393 — Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia · Phase 3 · completed
NCT05370703 — A Clinical Study to Evaluate the Effect of Mobile Applications "My A:Care" and "Smart Coach" on the Lipid-lowering Treat · completed
NCT05519514 — Bio-Equivalence Study of Budesonide Prolonged-release Tablets 9 Mg In Healthy Human Adult Subjects · Phase 1 · completed
NCT04784208 — A Study to Determine the Validity and Sensitivity of 'Questionnaire to Screen for HYpothyroidism' (Q'SHY) · unknown
NCT05175131 — Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00664430 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Abbott
Last refreshed: 18 January 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00664430.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing